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Abstract
IMPORTANCE Palliative care has shown benefits in reducing symptom intensity and quality of life in
patients with advanced cancer. However, high-quality evidence to support palliative care policy and
service developments for patients with long-term neurological conditions (LTNCs) is lacking.
OBJECTIVE To determine the effectiveness of a short-term integrated palliative care (SIPC)
intervention for people with LTNCs.
DESIGN, SETTING, AND PARTICIPANTS Multicenter, phase 3, randomized clinical trial conducted
from April 1, 2015, to November 30, 2017, with a last follow-up date of May 31, 2018, in 7 UK hospitals
with both neurology and palliative care services. A total of 535 patients with LTNCwere assessed for
eligibility and 350 were randomized. Inclusion criteria were patients 18 years or older with any
advanced stage of multiple sclerosis, motor neuron disease, idiopathic Parkinson disease multiple
system atrophy, or progressive supranuclear palsy. Data were analyzed from November 2018 to
March 2019.
INTERVENTIONS Patients were randomized 1:1 using minimizationmethod to receive SIPC
(intervention, n = 176) or standard care (control, n = 174).
MAINOUTCOMES ANDMEASURES Primary outcomewas change in 8 key palliative care
symptoms from baseline to 12-weeks, measured by the Integrated Palliative care Outcome Scale for
neurological conditions. Secondary outcomes included change in the burden of other symptoms,
health-related quality of life, caregiver burden, and costs. Data were collected and analyzed blindly
by intention to treat.
RESULTS A total of 350 patients (mean [SD] age 67 [12] years; years since diagnosis, 12 [range,
0-56]; 51%men; 49% requiring considerable assistance) with an advanced stage of LTNCwere
recruited, along with informal caregivers (n = 229). There were no between-group differences in
primary outcome (effect size, −0.16; 95% CI, −0.37 to 0.05), any other patient-reported outcomes,
adverse events, or survival. Although there was more symptom reduction in the SIPC group in
relation to mean change in primary outcome, the difference between the groups was not statistically
significant (−0.78; 95% CI, −1.29 to −0.26 vs −0.28; 95% CI, −0.82 to 0.26; P = .14). There was a
decrease in mean health and social care costs from baseline to 12 weeks −$1367 (95% CI, −$2450 to
−$282) in the SIPC group and −653 (95% CI, −$1839 to −$532) in the control group, but this
difference was not statistically significant (P = .12). SIPC was perceived by patients and caregivers as
building resilience, attending to function and deficits, and enabling caregivers.
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Abstract (continued)
CONCLUSIONSANDRELEVANCE In this study, SIPCwas not statistically significantly different from
standard care for the patient-reported outcomes. However, SIPCwas associatedwith lower cost, and
in qualitative analysis was well-received by patients and caregivers, and there were no safety
concerns. Further research is warranted.
TRIAL REGISTRATION isrctn.org Identifier: ISRCTN18337380
JAMA Network Open. 2020;3(8):e2015061. doi:10.1001/jamanetworkopen.2020.15061
Introduction
Palliative care, which focuses on improving quality of life (QoL) through amultidisciplinary and
holistic care approach, may offer an additional layer of support for those affected by chronic life-
limiting illnesses. Palliative care has shown benefits in symptom intensity and QoL in patients with
advanced cancer, and possible survival improvement.1-4 Despite experiencing problems and care
challenges similar to patients with advanced cancer, patients with chronic non-cancer conditions
including long-term neurological conditions (LTNCs) are less likely to receive palliative care.5,6
Neurological disorders are a major health burden, accounting globally for 10% of disability-
adjusted life-years and 17% of deaths.7 The LTNCs are a range of progressive neurodegenerative and
other neurological disorders that affect an individual and their family for the rest of their lives. These
conditions lead to substantial deterioration in QoL, require lifelong support from health and social
care services, and often are an immense strain physically and emotionally on informal caregivers and
family members.6,8,9 Health care costs increase in advanced disease and are higher in thosemost
severely affected.10
There is a lack of robust evidence to support service and policy developments that improve
palliative care provision for people with LTNCs.11,12 To date, there are 3 published small-scale pilot or
phase 2 randomized clinical trials of palliative care interventions in neurological conditions.13-15
Findings of these trials reported slight improvements in symptom burden without harmful effects;
however, they reported inconsistent effects on other outcomes (eg, QoL, caregiver burden). They
also differed in key trial components, such as study population, intervention, outcomemeasures, and
economic perspective.
Building on the phase 2 trial in multiple sclerosis (MS)13 and a longitudinal observational study
in advanced atypical parkinsonism,16 we undertook this phase 3 trial to evaluate the clinical
effectiveness and cost-effectiveness of short-term integrated palliative care (SIPC) among people
severely affected by LTNCs, for improving symptoms and other patient and caregiver outcomes. Our
primary null hypothesis was that there was no difference between study arms in their clinical
effectiveness.
Methods
StudyDesign and Setting
Pragmatic phase 3, multicenter, randomized clinical trial of the clinical effectiveness and cost-
effectiveness of SIPC for people with advanced LTNCs. Patients were recruited from 7 national
hospitals with both neurology services andmultiprofessional palliative care teams in the UK. Within
study sites, a broad range of services were offered, including voluntary and National Health Services
hospices, hospital and community basedmultidisciplinary palliative care, as well as tertiary and
secondary neurological services.5 This trial and its protocol were approved by the London South East
Research Ethics Committee. Patients and caregivers gave written informed consent. The trial
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protocol and interventionmanual are available in Supplement 1. This study followed the Consolidated
Standards of Reporting Trials (CONSORT) reporting guideline for randomized clinical trials..
Participants
Patients severely affected by LTNCs and their caregivers were identified by a neurologist or a clinical
nurse specialist and referred to the trial. The recruitment periodwas fromApril 1, 2015, to November
30, 2017, with a last follow-up date of May 31, 2018. Data were analyzed from November 2018 to
March 2019.
For patients, inclusion criteria included (1) adults (aged18 years) severely affected by
advanced or progressive stages of 1 of the following: MS (usually Expanded Disability Status Scale
score7.5 [range, 0 indicates no disability in any functional system and 10 indicates death due to
MS), all stages of motor neuron disease (MND), idiopathic Parkinson disease (IPD, Hoehn and Yahr
stages 4-5), progressive supranuclear palsy (adapted Hoehn and Yahr stages 3-5) and multiple
system atrophy (adapted Hoehn and Yahr stages 3-5); (2) an unresolved symptomwhich had not
responded to standard care; and (3) at least 1 of the following: an unresolved other symptom;
cognitive problems or complex psychological issues; communication or information problems or
complex social need. Exclusion criteria included already receiving specialist palliative care, lacking
mental capacity, and having no one available to advise on their behalf to provide proxy data.
For informal caregivers, inclusion criteria were adults identified by the patient as a person close
to themwho was able and willing to complete questionnaires. If the caregiver was unavailable or
declined participation, only the patient was enrolled.
Randomization andMasking
Randomization was undertaken independently by the UK Clinical Research Collaboration–registered
King’s Clinical Trials Unit. Following patient consent and baseline data collection, randomizationwas
performed in a 1:1 ratio, at the patient level withminimization for center, primary diagnosis (MS vs IPD
vs progressive supranuclear palsy, multiple system atrophy andMND), and cognitive impairment
(capacity vs impaired or lacking capacity). The data collectors (W.G. and I.J.H.) and the statistical and
health economic analysis team (W.G., R.W., and D.Y.) were blinded to the group allocation until after
themain analyses were completed and reported to the study steering committee.
SIPC Intervention
SIPC focused on a comprehensive assessment, personalized care planning, case management and
care coordination, and advising existing care providers. It was developed and evaluated using the
Medical Research Council framework for evaluating complex interventions. SIPC was delivered by
existingmultiprofessional palliative care teams, linkedwith local neurology services. All staff involved
in the delivery of the intervention were provided with a standard manual (Supplement 1) and face-
to-face training in advance of the trial commencing. The intervention manual described the core
elements to be covered when assessing patients as part of SIPC as well as theminimum standards for
capturing and reporting delivery of SIPC.
SIPC usually lasted from 6 to 8weeks from referral. Following referral, a key worker contacted
the patient within 2 working days to arrange a visit within the next 5 working days. At this initial visit,
a comprehensive palliative care assessment was undertaken considering both patient and caregiver
and family needs. A problem list was generated, and a proposed care plan was developed to which
the patient and their family agreed. The second contact (face-to-face or telephone) normally
occurred within 2 weeks of the first visit to review progress with the care plan. The final contact
involved a review of outcomes from actions already taken before discharge to local services as
appropriate. The control arm continued to receive usual care services until after 12-weeks at which
point they were referred to SIPC. A summary of the intervention is presented in Table 1.
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Data Collection
Data were collected at baseline and then 6-weekly until 24-weeks post randomization. Trained
research nurses/researchers assisted as required in self-completion of patient and caregiver
questionnaires according to the standardized schedule during their face-to-face visits. Ethnicity was
self-defined by participants. We collected this data as it is a known confounder for accessing health
care services. Caregivers usually self-completed their questionnaires during the patient interview. For
adults lacking capacity, baseline and outcomemeasures were obtained from the informal caregiver.
The qualitative study comprised interviews with patients and caregivers after SIPC was completed.
Outcomes
The outcomemeasures used in this study are presented in eTable 1 in Supplement 2. The primary
outcomewas the change score between baseline and at 12-weeks in 8 symptoms (pain, shortness of
breath, nausea, vomiting, constipation, spasms, difficulty sleeping, andmouth problems) as
measured by the Integrated Palliative care Outcome Scale for Neurological conditions (IPOS
Neuro-S8; each itemwas rated on a 5-point Likert scale in which 0 indicates no problem and 4
indicates an overwhelming problem; total score ranges from0-32).17 Secondary outcomes for
patients were changes in other palliative care symptoms, palliative care needs, psychological stress,
health-related QoL and satisfaction. For caregivers, outcomes included caregiver burden and
positivity as well as satisfaction. Patient-reported health service use was collected using the Client
Services Receipt Inventory.18 For patients unable to convey outcomes, we collected caregiver’s
assessment of patient’s problems and service use. As safetymeasures, wemonitored serious adverse
events, adverse events, and survival.
Data Analysis
Given 80% power and 2-tailed significance of 5%, it was estimated that we needed to recruit 356
patients (178 per arm) to detect a small to medium effect size of 0.3 in the primary outcome,
equivalent to a score change of 1.0 in the IPOS Neuro-S8 from baseline to 12 weeks
postrandomization. Theminimal clinically important difference in IPOS Neuro-S8 as estimated by a
third of the standard deviation was 1.1.17 This estimation assumed a correlation coefficient of 0.4
Table 1. Details of SIPC and Standard Care
Timeline SIPC Standard care
Consent and baseline interview Baseline research interview and consent before
randomization
Baseline research interview and consent before
randomization
Randomization
2 working days from receiving referral Palliative care assessment within 2 working days NA
Weeks
1-6 Palliative care, including assessment, treatment, referral,
review
NA
6 Research interview 6 weeks post randomization. Research interview 6 weeks postrandomization
6-8 Palliative care continues lasting 6-8 weeks, with referral
on for those needing long-term care
NA
12-weeks (primary end point) Research interview 12 weeks postrandomization Research interview 12 weeks postrandomization
2 working days from receiving referral (following
completion of 12-week research interview)
NA Standard care group now offered palliative care within 2
working days of receiving referral
Weeks
12-18 Discharge from palliative care team (if referred to
community team, this continues from this point)
Palliative care, including assessment, treatment, referral,
review
18 Research interview 18 weeks postrandomization Research interview 18 weeks post randomization
18-20 NA Palliative care continues lasting 6 to 8 weeks, with
referral on for those needing long-term care
24 Final research interview 24 weeks postrandomization Final research interview 24 weeks postrandomization
24-26 NA Discharge from palliative care team (if referred to
community team, this continues from this point)
Abbreviations: NA, not applicable; SIPC, short-term integrated palliative care.
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between baseline and 12-week scores and 17% attrition. The parameters for sample size estimation
were from previous studies.13,16
This paper reports baseline and at 12-week data only. Missing data were summarized according
to the Methods of Researching End of Life Care classification.19 The mechanism of missing was
assumedmissing at random. Multiple imputation using chained equations was used to impute
missing data. Twenty copies of imputed values were generated for each variable with missing data.
For baseline and outcome data, observations with complete data at both times were reported.
Continuous variables were summarized using mean (standard deviation) and median (range) as
appropriate. Categorical variables were reported as frequency counts and percentage.
Intention-to-treat analysis was carried out using generalized linear mixedmodel with center
modeled as a random effect, adjusting for baseline score. Themean change scores from baseline to
12 weeks, effect sizes and their 95% CIs were reported. Effect sizes were calculated frommodel-
based point estimates (95% CIs) of effect for individual outcomes divided by respective SDs, derived
from standard errors using themethod described previously.20 Survival was compared using the
2-sample t test and adverse events were compared using the χ2 test.
Six sensitivity analyses were conducted to assess the robustness of the findings from themain
analysis: (1) the comparison between arms also accounted for the difference in ethnicity as there
were moreWhite individuals in SIPC than in the control arm (94.3% vs 86.2%; P = .009); (2) the 2
participants who were deemed ineligible postrandomization were excluded, thus the sample size for
this analysis was 348; (3) we assessed differences in change scores between trial arms in complete
patient data; (4) we assessed differences in change scores between trial arms in caregiver data; (5)
we used complete patient data, if available at both baseline and week 12, and imputed proxy
caregiver data if not; and (6) we evaluated the primary and secondary outcomes for patients withMS
only to compare the effects of SIPC in this trial with that of the Phase 2MS trial.13
The interaction effect between treatment and trial center on outcomes was explored by
including a product term in the generalized linear mixedmodels. The P values were examined.
To determine the cost of SIPC, a base case incremental analysis from an NHS perspective was
conducted. We valued health and social care use from the Client Services Receipt Inventory for the
past 3 months at baseline and at 12 weeks bymultiplying use by specific unit cost data from standard
sources (eTable 9 in Supplement 2).
All significance tests were 2-sided at the level of .05 (primary and cost outcomes) or 0.0045
(secondary outcomes, Bonferroni correction to control for multiple testing 0.05 divided by 11 [total
number of tests on the secondary outcomes]). Statistical analyses were performed in parallel using
SAS, version 9.4 (SAS Institute Inc) and Stata, version 14 (StataCorp Inc).
Qualitative interviews were digitally recorded, transcribed verbatim, and anonymized prior to
analysis. The data were analyzed thematically using the Coffey and Atkinson iterative approach.21
Results
A total of 535 participants were assessed for eligibility. Among the 492 participants whomet
eligibility criteria, we recruited and randomized 350 patients and 229 caregivers across 7 centers,
with 176 patients randomized to SIPC and 174 patients randomized to standard care (Figure).
Patients’ mean (SD) age was 67 (12), and 179 (51%) weremen (Table 2). Multiple sclerosis (N = 148)
and IPD (N = 140)were the 2most common diagnosed conditions. Patients had been livingwith their
conditions for a median of 12 years (range, 0-56 years), 39 patients (11%) had cognitive impairment
and approximately 60% of patients required either considerable assistance or total care for
daily living.
Primary and Secondary Clinical Outcomes
There were no statistically significant differences between trial arms for the primary outcome (effect
size, −0.16; 95% CI, −0.37 to 0.05) or any of the secondary outcomes (effect size range, −0.20 to
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0.12; P value range, 0.06 - 0.90). There was a small but statistically significant reduction in symptom
burden at 12weeks in the SIPC group (IPOSNeuro-S8, −0.78; 95%CI, −1.29 to −0.26) (Table 3). Most
other patient outcomes were consistent: score changes in the control arm had either a smaller but
statistically insignificant improvement or a greater decrease than the corresponding figures in the
SIPC group. Results of the sensitivity analyses confirmed the robustness of the findings (eTables 2-7
in Supplement 2). None of the interaction between treatment and site on primary outcome or
secondary outcomes was statistically significant. Neither adverse events nor survival was statistically
different between the 2 groups
Adverse Events and Survival Outcome
There were 5 deaths, 13 hospitalizations, and 2 emergency department visits up to 12 weeks in the
SIPC group. The corresponding figures for the control arm were 3 deaths, 12 hospitalizations, and 5
emergency department visits up to 12 weeks. Survival between the 2 groups was comparable (11.6 vs
11.8weeks). Neither adverse events (P = .61) nor survival (P = .28)was statistically different between
the 2 groups.
Health Economic Outcomes
There was a decrease in mean (95% CI) health and social care costs from baseline to 12 weeks −$1367
(95% CI, −$2450 to −$282) in the SIPC group and −653 (95% CI, −$1839 to −$532) in the control
group (eTable 10 in Supplement 2). No significant differences were found between groups for the
change scores of EuroQoL 5-dimension index score (0.04; 95% CI, −0.02 to 0.09; P = .08).
Results of Qualitative Analysis
Patients (N = 26) and caregivers (N = 16) participated in 26 qualitative interviews from 3 trial centers
(London, Brighton, Ashford-Surrey). The characteristics of participants are shown in eTable 11-12 in
Figure. Consort Diagram Showing the Flow of Patients in OPTCARENeuro Trial
535 Patients assessed for eligibility
492 Eligible
176 Randomized to receive SIPC intervention 174 Randomized to receive standard care
165 At week 6
176 Analyzed (using multiple imputation)
11 Lost to follow-up
4 Deaths
7 Withdrawals
163 At week 12
163 Received allocation
2 Lost to follow-up
1 Death
1 Withdrawal
171 At week 6
174 Analyzed (using multiple imputation)
3 Lost to follow-up
1 Death
2 Withdrawals
164 At week 12
158 Received allocation
7 Lost to follow-up
2 Deaths
5 Withdrawals
350 Randomized
43 Excluded (not meeting eligibility criteria)
142 Excluded
112 Declined
30 Other reasons
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Table 2. Demographic and Clinical Characteristics of Patients and Caregivers
Variable
No. (%)
Patients Caregivers
SIPC Standard C SIPC Standard C
No. 176 174 121 108
Age, mean (SD), y 67.3 (10.9) 66.4 (12.6) 63.3 (13.3) 65.3 (13.4)
Sex
Male 86 (48.9) 93 (53.5) 41 (33.9) 40 (37.0)
Female 90 (51.1) 81 (46.6) 80 (66.1) 68 (63.0)
Marital status
Single 16 (9.1) 19 (10.9) 7 (5.8) 7 (6.5)
Widowed 19 (10.8) 19 (10.9) 4 (3.3) 6 (5.6)
Married/civil partner 114 (64.8) 117 (67.2) 109 (90.1) 91 (84.3)
Divorced/separated 26 (14.8) 18 (10.3) 1 (0.8) 4 (3.7)
Not done/unknown 1 (0.6) 1 (0.6) NA NA
Living status
Alone 35 (19.9) 30 (17.2) 4 (3.3) 5 (4.6)
Spouse/partner and/or children 125 (71.0) 119 (68.4) 109 (90.1) 91 (84.3)
Friend(s)/with others 16 (9.1) 25 (14.4) 8 (6.6) 12 (11.1)
Education
No formal education 67 (38.1) 72 (41.4) 51 (42.2) 45 (41.7)
Upper secondary to postsecondary
vocational qualification
53 (30.1) 63 (36.2) 37 (30.6) 29 (26.9)
Tertiary education 55 (31.3) 36 (20.7) 30 (24.8) 32 (29.6)
Not done/missing 1 (0.6) 3 (1.7) 3 (2.5) 2 (1.9)
Race/ethnicity
White 166 (94.3) 150 (86.2) 113 (93.4) 98 (90.7)
Other ethnic groupa 9 (5.1) 23 (13.2) 8 (6.6) 10 (9.3)
Employment
No 173 (98.3) 167 (96.0) 86 (71.1) 76 (70.4)
Yes 3 (1.7) 7 (4.0) 35 (28.9) 32 (29.6)
Relationship to patient
Spouse/partner NA NA 97 (80.2) 80 (74.1)
Son/daughter NA NA 17 (14.1) 12 (11.1)
Other NA NA 0 4 (3.7)
Having illness
Yes NA NA 70 (57.9) 70 (64.8)
No NA NA 41 (33.9) 36 (33.3)
Feelings on present income
Living comfortably 58 (33.0) 60 (34.5) NA NA
Coping 85 (48.3) 77 (44.3) NA NA
Difficult 12 (6.8) 12 (6.9) NA NA
Very difficult 7 (4.0) 7 (4.0) NA NA
Not done/unknown 14 (8.0) 18 (10.3) NA NA
Diagnosis
Multiple sclerosis 74 (42.1) 74 (42.5) NA NA
Idiopathic Parkinson disease 71 (40.3) 69 (39.7) NA NA
Multiple system atrophy 7 (4.0) 5 (2.9) NA NA
Progressive supranuclear palsyb 13 (7.4) 14 (8.1) NA NA
Motor neuron disease 11 (6.3) 12 (6.9) NA NA
Time since diagnosis, median (range), y 12.3 (0-56) 12.4 (0-46) NA NA
Comorbidities
Yes 134 (76.1) 117 (67.2) NA NA
No 42 (23.9) 57 (32.8) NA NA
(continued)
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Supplement 2. Similar to themain sample, patients mostly hadMS (69%) and had lived with their
condition amedian of 11 years. The themes of SIPC assessed by patients and caregivers included
adapting to losses and building resilience, attending to function, deficits andmaintaining stability,
and enabling carers to care (eTable 13 in Supplement 2).
Discussion
In this randomized clinical trial of palliative care in people with LTNCs, none of the evaluated
outcomes were significantly different between the 2 groups, nor were adverse events, survival, or
withdrawals. However, we found a small and statistically significant reduction in both the primary
outcome and care costs in the intervention group. Health economic analyses suggested that SIPC
may deliver better outcomes at a lower cost than standard care.
The heterogeneity of the disorders studiedmay have been factors in the non-significant results
of the trial. IPD, MND, andMS differ in pathophysiology, clinical profiles, natural history as well as
endophenotypes. Many consider IPD itself to be a syndrome23 and subtypes within MND andMS are
also well recognized. Aspects related to non-motor symptoms of these disorders, particularly IPD,
may also be substantially different fromMS andMND, andmay lead to the data being difficult to
capture.24,25 Variations across centers, for example how the eligibility criteria were applied to recruit
patients (eTable 8 in Supplement 2), the way the intervention was organized and delivered,5 may
also have played a role in the intervention effect. Although the sample size was inflated to account
for the heterogeneity when planning the study and training had been provided to ensure the
consistency of key trial elements, it appeared that the heterogeneity was largely underestimated.
The observed effect of SIPC in this trial was overall much smaller than that of the phase 2 trial (−0.14
vs −0.80).26
Outcomemeasures may be another factor in the interpretation of the intervention effects. The
primary outcomewas selected based on the 5 symptoms that weremost responsive to the palliative
care intervention in the phase 2 trial and additional symptoms from a longitudinal observational
study of advanced Parkinson disease and atypical parkinsonism.13,16 Preliminary psychometric
evaluations found that themeasure exhibited good psychometric properties.17,27 In this trial, several
items of the IPOSNeuro-S8 aswell as the IPOSNeuro-S24 showed floor effects at baseline. However,
per the eligibility criteria, the patients recruited should have unresolved symptoms, which the
referring clinicians deemed to require input from specialist palliative care, especially in non-motor
symptoms. Not all symptomsmay be adequately captured by our outcomemeasures; therefore,
further refinement of the outcomemeasures may be necessary.
Table 2. Demographic and Clinical Characteristics of Patients and Caregivers (continued)
Variable
No. (%)
Patients Caregivers
SIPC Standard C SIPC Standard C
Consent
Patient consent 157 (89.2) 154 (88.5) NA NA
Personal consultee assent 19 (10.8) 20 (11.5) NA NA
Functional status as measured by AKPSc
Totally bedfast 3 (1.7) 4 (2.3) NA NA
Almost completely bedfast 5 (2.8) 5 (2.9) NA NA
In bed >50% of the time 10 (5.7) 11 (6.3) NA NA
Requires considerable assistance 77 (43.8) 93 (53.5) NA NA
Requires occasional assistance 54 (30.7) 44 (25.3) NA NA
Cares for self 19 (10.8) 14 (8.1) NA NA
Normal activity with effort 7 (4.0) 2 (1.2) NA NA
Not available/applicable/not done 1 (0.6) 1 (0.6) NA NA
Abbreviations: NA, not applicable; SIPC, short-term
integrated palliative care.
a Other includes mixed/multiple ethnic groups, Asian/
Asian British, Black/African/Caribbean/Black British,
other ethnic group, don't know, prefer not to say, not
available or not applicable, not done, or unknown.
b Includes N = 2 patients with Corticobasal
Degeneration.
c The Australia-modified Karnofsky Performance Scale
(100 – Normal to 0 – Dead).
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Table 3. Results of Primary and SecondaryaOutcomes UsingMultiply Imputed Data FromAll Recruited Patients
Measure
SEM (95% CI)
P valuebSIPC (N = 176) Standard care (N = 174) Effect size
Primary outcome
IPOS Neuro-S8
Baseline 6.89 (6.24 to 7.54) 6.96 (6.34 to 7.58) NA NA
12-wk 6.11 (5.46 to 6.77) 6.68 (6.02 to 7.34) NA NA
Change score −0.78 (−1.29 to −0.26) −0.28 (−0.82 to 0.26) −0.16 (−0.37 to 0.05) .14
Secondary patient
outcome
IPOS Neuro-S24
Baseline 26.69 (24.23 to 29.15) 27.16 (24.57 to 29.75) NA NA
12-wk 24.74 (22.10 to 27.37) 26.27 (23.58 to 28.96) NA NA
Change score −1.95 (−4.38 to 0.48) −0.89 (−3.15 to 1.36) −0.13 (−0.34 to 0.08) .22
IPOS Neuro 8
Baseline 11.43 (10.07 to 12.79) 11.58 (10.09 to 13.08) NA NA
12-wk 10.59 (9.09 to 12.09) 11.80 (10.34 to 13.26) NA NA
Change score −0.84 (−2.09 to 0.40) 0.21 (−1.25 to 1.68) −0.20 (−0.41 to 0.01) .06
IPOS Neuro
Baseline 47.36 (41.94 to 52.78) 46.72 (40.93 to 52.51) NA NA
12-wk 43.14 (35.28 to 51.00) 44.22 (37.55 to 50.89) NA NA
Change score −4.22 (−10.87 to 2.43) −2.50 (−8.37 to 3.37) −0.07 (−0.28 to 0.15) .53
HADS anxiety
Baseline 7.78 (6.78 to 8.77) 7.51 (6.52 to 8.50) NA NA
12-wk 7.43 (6.28 to 8.58) 7.59 (6.53 to 8.66) NA NA
Change score −0.35 (−1.12 to 0.43) 0.08 (−0.65 to 0.81) −0.12 (−0.33 to 0.09) .27
HADS depression
Baseline 8.13 (7.29 to 8.97) 8.31 (7.47 to 9.16) NA NA
12-wk 7.96 (7.03 to 8.88) 8.22 (7.35 to 9.09) NA NA
Change score −0.17 (−0.79 to 0.45) −0.09 (−0.78 to 0.59) −0.04 (−0.25 to 0.17) .69
EQ-5D VAS
Baseline 52.72 (47.91 to 57.53) 52.25 (47.01 to 57.49) NA NA
12-wk 53.69 (48.03 to 59.34) 50.75 (45.36 to 56.14) NA NA
Change score 0.97 (−5.01 to 6.94) −1.50 (−8.05 to 5.05) 0.12 (−0.09 to 0.33) .27
SEMCD
Baseline 5.39 (4.89 to 5.89) 5.13 (4.63 to 5.64) NA NA
12-wk 5.28 (4.75 to 5.82) 4.94 (4.41 to 5.47) NA NA
Change score −0.10 (−0.60 to 0.40) −0.19 (−0.70 to 0.31) 0.10 (−0.11 to 0.31) .37
FAMCARE P16
(patient version)
Baseline 50.33 (46.66 to 54.00) 50.30 (47.08 to 53.53) NA NA
12-wk 48.08 (43.75 to 52.41) 47.41 (43.52 to 51.31) NA NA
Change score −2.26 (−6.05 to 1.53) −2.89 (−6.23 to 0.45) 0.04 (−0.17 to 0.25) .70
Secondary caregiver
outcome
ZBI 12
Baseline 18.25 (15.59 to 20.90) 18.68 (16.28 to 21.08) NA NA
12-wk 18.60 (15.93 to 21.27) 18.92 (16.28 to 21.55) NA NA
Change score 0.35 (−0.98 to 1.68) 0.24 (−1.15 to 1.64) 0.01 (−0.20 to 0.22) .90
ZBI Positivity
Baseline 18.97 (17.36 to 20.59) 18.72 (17.05 to 20.38) NA NA
12-wk 18.87 (17.08 to 20.67) 18.12 (16.15 to 20.10) NA NA
Change score −0.10 (−1.43 to 1.23) −0.59 (−1.98 to 0.79) 0.09 (−0.12 to 0.30) .40
(continued)
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Limitations
This study has limitations. The sample was largely composed of patients with MS and IPDwho tend
to have a longer disease course. It is possible that the baseline symptom profiles and therefore the
subsequent experience of SIPC are different for patients with LTNCs with a more rapid progression.
Although every effort was made to standardize SIPC and our fidelity data showed that the
intervention overall managed well (eTable 14 in Supplement 2), there were differences across
centers. The intraclass correlation coefficient of 0.12 for IPOS Neuro-S8 was high but was not
accounted for in our sample size estimation. The intervention teamswere amix of hospice based and
hospital based, which led to differences in themake-up of theirmultidisciplinary teams aswell as the
services they were able to offer. There may have been contamination whereby participants in the
control arm received components of SIPC.
Conclusions
In this randomized clinical trial of SIPC vs standard care, there were no differences in patient reported
outcomes or adverse events. Refining referral criteria to better match patients to SIPC and
intervention optimizationmay help to support wider implementation of this new care model in
practice.
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